Bigul

SHILPA MEDICARE LTD. - 530549 - Sub: Outcome Of Board Meeting Held On 15Th June, 2020. Ref: Regulation 30 Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015; Scrip Code: BSE- 530549/ Stock Symbol: NSE - SHILPAMED

With reference to the captioned subject, please note that the Board of Directors of the Company, at its meeting held today, inter-alia, considered and approved the Audited Financial Results (Standalone and Consolidated) as per Indian Accounting Standards (Ind- AS) along with the Independent Auditor's Report thereon for the Quarter and Year ended 31st March, 2020. A copy of the said Audited Financial Results along with the Independent Auditor's Report thereon is enclosed herewith. The meeting commenced at 14:30 hours and concluded at 18:15 HOURS. This is for your information and necessary records.
15-06-2020
Bigul

SHILPA MEDICARE LTD. - 530549 - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.

SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/06/2020 ,inter alia, to consider and approve With reference to the subject cited above, we wish to inform you that a meeting of the Board of Directors of Shilpa Medicare Limited will be held on Monday, the 15th Day of June, 2020 to inter alia transact the following items of business: Approval of the Audited Standalone and Consolidated Financial Results of the Company for Fourth Quarter and the Financial Year ended 31st March, 2020. This is for your information and records.
10-06-2020

Gladiator Stocks - Shilpa Medicare: ICICI Securities

According to ICICI Securities, Buy Shilpa Medicare in the range of Rs 440.00458.00 for target price of Rs 535.00 with a stop loss of Rs 405.00. Time Frame: Six months.
05-06-2020

Shilpa Medicare share price rises nearly 5% on launching anti-cancer drug

IBRUSHIL (Ibrutinib 140 mg) capsules is being manufactured in the state-of-the-art US-FDA approved manufacturing facility.
28-05-2020
Bigul

SHILPA MEDICARE LTD. - 530549 - Sub: Intimation U/R 30 Of The SEBI(LODR) Regulations- Reg. Ref: Stock Code: NSE: SHILPAMED/BSE-530549

Shilpa Medicare Launches Three Affordable Anticancer Drug in Indian Market within Four Months, the Third Launch 'IBRUSHIL' is for the treatment of Leukemia
28-05-2020
Bigul

SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Meeting Updates

Dear Sir, This is to intimate that the Board of Directors of the Company at its meeting held on 05th May, 2020, approved the following items of business: 1.To promote Whole Owned Subsidiaries for the business operations of the Company in Canada (North America) and Spain (Europe) . Kindly take the record of the same.
05-05-2020
Bigul

SHILPA MEDICARE LTD. - 530549 - Compliance Certificate For Half Year Ended 31St March, 2020

With reference to the subject cited above, please find attached herewith the Compliance Certificate under Regulation 40(9) of SEBI (LODR) Regulations, 2015, issued by the Practicing Company Secretary M/s P.S Rao & Associates.
25-04-2020
Bigul

SHILPA MEDICARE LTD. - 530549 - Sub: Compliance Certificate For Half Year Ended 31St March, 2020. Ref: Regulation 7(3) Of SEBI (LODR) Regulations, 2015.

This is to certify that the Company, M/s Shilpa Medicare Limited having its registered office at 12-6-214/A-1, Hyderabad Road, Raichur ,Karnataka - 584135 has been maintaining all the activities in relation to both physical and electronic share transfer facility as specified under Regulation 7(2) of SEBI (LODR) Regulations, 2015 with M/s Karvy Fintech Private Limited, a SEBI Registered Share Transfer Agent, having their corporate office at Karvy Selenium Tower B, Plot No.31 & 32, Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad - 500 032. Further, a copy of letter received from M/s Karvy Fintech Private Limited confirming the compliance of provisions of Regulation 7 (2) of the SEBI (LODR) Regulations, 2015, is enclosed herewith
25-04-2020

Shilpa Medicare share price gains nearly 3% on launch of anti-cancer drug

The products are being manufactured and supplied from the state-of-the-art US-FDA approved manufacturing facility.
24-04-2020
Next Page
Close

Let's Open Free Demat Account